Life Systems Medical is pleased to announce that Cardiac Contractility Modulation (CCM) delivered by the Optimizer implantable pulse generator has been included as a treatment consideration by the European Society of Cardiology for patients with heart failure, reduced ejection fraction, NYHA Classes II-III with normal QRS duration (<120ms). The 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure were published on the 20th of May 2016 in the European Heart Journal. CCM is described as a non-excitatory electrical stimulation of the ventricle during the absolute refractory period to enhance contractile performance without activating extra systolic contractions, and the evaluated patient profile as outlined in the Guidelines includes: • Symptomatic HF despite optimal medical therapy • NYHA Class II – III • Normal QRS Durations <120ms The Optimizer IVs is paired to conventional pacing leads to complete the system and deliver optimal therapy. The Optimizer IVs is approved by the Therapeutic Goods Administration (TGA) and is available for commercial use in Australia. The comment on Cardiac Contractility Modulation as a treatment consideration in the ESC Guidelines is further validation of the benefits of CCM in addition to the trials conducted in Europe and the USA. “As a company we are pleased to introduce this solution to Australian patients suffering from Heart Failure who are symptomatic despite optimal medical therapy, and we continue to see the benefits first hand of CCM in patients already implanted in Australia” said General Manager Shannon Tolley. About Life Systems Medical
Life Systems Medical exclusively distributes highly specialised medical technology in fields such as cardiology, vascular surgery and interventional radiology.
